Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lasers Surg Med. 2022 Feb;54(2):230-236. doi: 10.1002/lsm.23459. Epub 2021 Sep 6.
Various laser therapies have been introduced in scar management. However, pain during treatment has limited the application of laser therapy in pediatrics.
To evaluate whether the use of the low-energy mode of a carbon dioxide (CO ) laser improves hypertrophic scars in a pediatric population.
This prospective, randomized, split-scar trial was designed to assess the safety and efficacy of low-energy CO laser use. Patients aged <12 years with hypertrophic scars were enrolled. Each hypertrophic scar was equally divided into three parts: the two ends of each scar were randomly assigned to control and experimental groups, and the center portion was considered a transition zone and was not included in the analysis. A total of three laser treatments were performed at 1-month intervals. Scar scale scores 6 months after the final treatment was the primary outcome. Additionally, the Visual Analog Scale (VAS) was used to evaluate pain after each treatment.
Of the 23 patients enrolled, 20 completed the study. The total Patient and Observer Scar Assessment Scale (POSAS) score at the 6-month follow-up was significantly lower for the treated site (44.95 for the treated group vs. 64.85 for the control group, p < 0.0001). Both the patient and observer POSAS scores showed an obvious difference between the treated and control groups (19.95 vs. 29.95 for patient scores, respectively, p < 0.0001, and 26.00 vs. 34.90 for observer scores, respectively, p < 0.0001). All observer and patient scores describing pain, pruritus, color, stiffness, and thickness were statistically different and favored the treated site. No significant difference was found in patient score of irregularity. The average VAS therapeutic pain score was 3.5 ± 1.43 out of 10.
Low-energy CO fractional laser therapy improved hypertrophic scars in a pediatric population. Therefore, for children with hypertrophic scar, low-energy CO laser with less procedure pain may be more appropriate.
各种激光疗法已被引入瘢痕管理中。然而,治疗过程中的疼痛限制了激光疗法在儿科中的应用。
评估二氧化碳(CO)激光低能量模式是否能改善小儿人群的增生性瘢痕。
本前瞻性、随机、瘢痕分割试验旨在评估低能量 CO 激光使用的安全性和有效性。招募年龄<12 岁的增生性瘢痕患者。每个增生性瘢痕均等分为三部分:瘢痕的两端随机分为对照组和实验组,中间部分视为过渡区,不纳入分析。每 1 个月进行 3 次激光治疗。末次治疗后 6 个月的瘢痕量表评分是主要结局。此外,还使用视觉模拟评分(VAS)评估每次治疗后的疼痛。
23 例患者中,20 例完成了研究。治疗部位的总患者和观察者瘢痕评估量表(POSAS)评分在 6 个月随访时显著降低(治疗组为 44.95,对照组为 64.85,p<0.0001)。患者和观察者 POSAS 评分均显示治疗组与对照组之间存在明显差异(患者评分分别为 19.95 vs. 29.95,p<0.0001,观察者评分分别为 26.00 vs. 34.90,p<0.0001)。描述疼痛、瘙痒、颜色、硬度和厚度的所有观察者和患者评分均有统计学差异,且均有利于治疗部位。患者评分的不规则性无显著差异。平均 VAS 治疗疼痛评分为 3.5±1.43(满分 10 分)。
低能量 CO 分束激光治疗改善了小儿增生性瘢痕。因此,对于有增生性瘢痕的儿童,低能量 CO 激光可能更适合,因为其治疗过程疼痛较轻。